Iams Wealth Management LLC Has $523,000 Stock Holdings in Stryker Co. (NYSE:SYK)

Iams Wealth Management LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 32.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,452 shares of the medical technology company’s stock after acquiring an additional 357 shares during the quarter. Iams Wealth Management LLC’s holdings in Stryker were worth $523,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in SYK. Masso Torrence Wealth Management Inc. acquired a new position in shares of Stryker during the 4th quarter worth $874,000. Forsta AP Fonden increased its holdings in Stryker by 0.3% in the 4th quarter. Forsta AP Fonden now owns 92,253 shares of the medical technology company’s stock worth $33,216,000 after purchasing an additional 300 shares in the last quarter. Nvest Financial LLC boosted its position in shares of Stryker by 46.7% during the 4th quarter. Nvest Financial LLC now owns 2,313 shares of the medical technology company’s stock valued at $833,000 after purchasing an additional 736 shares in the last quarter. Foster Group Inc. bought a new stake in shares of Stryker during the 4th quarter valued at about $216,000. Finally, Fulton Breakefield Broenniman LLC boosted its position in shares of Stryker by 0.9% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 35,830 shares of the medical technology company’s stock valued at $12,901,000 after purchasing an additional 307 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SYK. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Wednesday. BTIG Research upped their price target on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Wells Fargo & Company upped their price target on Stryker from $405.00 to $427.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Robert W. Baird upped their price target on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $412.55.

Stryker Price Performance

NYSE SYK opened at $393.49 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock’s fifty day moving average price is $376.44 and its 200 day moving average price is $361.98. Stryker Co. has a 1 year low of $314.05 and a 1 year high of $406.19. The company has a market cap of $150.00 billion, a price-to-earnings ratio of 42.07, a PEG ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same period last year, the business earned $3.46 EPS. As a group, equities research analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Insider Activity at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.50% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.